In the early 2000s, computational chemistry faced a bottleneck as stubborn as a stuck door in a blast-proof vault. It was called the docking problem. Researchers would spend months synthesizing a molecule they hoped would bind to a disease-causing protein, only to find it was a poor fit—like trying to force a square peg into a round hole. The process was slow, expensive, and demoralizing. Then, a modest laboratory at The Scripps Research Institute in La Jolla, California, decided to stop hammering the door and instead redesign the key.
The real turning point came in 2020. When SARS-CoV-2 emerged, researchers around the globe turned to Vina not as a luxury, but as a necessity. With no time for slow, painstaking methods, they used it to virtually screen existing drug libraries against the viral main protease. The speed of Vina allowed a distributed computing project—a kind of crowdsourced supercomputer—to evaluate billions of interactions in weeks. While no "silver bullet" drug emerged from those screens, the process changed forever. Vina had democratized computational drug discovery. A single researcher with a laptop could now do what a well-funded lab needed a cluster for a decade earlier. autodock vina
That was the conceptual spark. They decided to break the unwritten rule of docking: that accuracy and speed were eternal enemies. Forli began rewriting the search algorithm from scratch, replacing the sluggish genetic algorithm with a combination of iterative local search and what he called a "broyden–fletcher–goldfarb–shanno" (BFGS) quasi-Newton method. It was a mathematical mouthful, but its effect was profound. Instead of randomly sampling poses like a blindfolded miner, the new method intelligently rolled downhill toward the lowest energy, learning the terrain as it went. In the early 2000s, computational chemistry faced a
한국어
